You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNiacin
Accession NumberDB00627  (APRD00536, NUTR00042)
TypeSmall Molecule
GroupsApproved, Investigational, Nutraceutical
Description

A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem]

Structure
Thumb
Synonyms
3-carboxypyridine
3-Pyridinecarboxylic acid
3-Pyridylcarboxylic acid
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Anti-pellagra vitamin
beta-Pyridinecarboxylic acid
M-Pyridinecarboxylic Acid
Niacin
Nicotinic Acid
Nikotinsaeure
P.P. factor
Pellagra preventive factor
PP Factor
Pyridine-beta-carboxylic acid
pyridine-β-carboxylic acid
Vitamin B3
β-pyridinecarboxylic acid
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
B-3 500mg Continuous Releasedtablet (extended-release)500 mgoralGahler Enterprises Ltd.1981-12-312000-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacintablet, film coated, extended release500 mg/1oralZydus Pharmaceuticals USA Inc2014-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release1000 mg/1oralZydus Pharmaceuticals USA Inc2014-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release750 mg/1oralZydus Pharmaceuticals USA Inc2014-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacin Ctr Srt 500mgtablet (extended-release)500 mgBioenergy Inc.1981-12-311998-06-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Inj 100mg/mlsolution100 mgintramuscular; intravenousKripps Pharmacy Ltd.1979-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Pwr 800mg/1.25mlpowder800 mgoralKripps Pharmacy Ltd.1980-12-312012-06-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspantablet, film coated, extended release500 mg/1oralAbb Vie Inc.2010-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release750 mg/1oralCarilion Materials Management1997-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet (extended-release)1000 mgoralSunovion Pharmaceuticals Canada Inc2005-03-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspantablet, film coated, extended release1000 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release500 mg/1oralCarilion Materials Management2010-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet (extended-release)500 mgoralSunovion Pharmaceuticals Canada Inc2005-03-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspantablet, film coated, extended release750 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release1000 mg/1oralCardinal Health2010-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release1000 mg/1oralRebel Distributors Corp1997-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release500 mg/1oralCardinal Health2010-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release500 mg/1oralRebel Distributors Corp2010-03-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release500 mg/1oralPhysicians Total Care, Inc.2009-07-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release1000 mg/1oralAbb Vie Inc.1997-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release750 mg/1oralPhysicians Total Care, Inc.2005-03-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release1000 mg/1oralDispensing Solutions, Inc.1997-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release750 mg/1oralAbb Vie Inc.1997-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet, film coated, extended release1000 mg/1oralPhysicians Total Care, Inc.2009-05-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspantablet (extended-release)750 mgoralSunovion Pharmaceuticals Canada Inc2005-03-152012-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspantablet, film coated, extended release500 mg/1oralDispensing Solutions, Inc.2010-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspan ERtablet, film coated, extended release500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niaspan Fcttablet (extended-release)500 mgoralSunovion Pharmaceuticals Canada Inc2009-05-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspan Fcttablet (extended-release)1000 mgoralSunovion Pharmaceuticals Canada Inc2009-05-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niaspan Fcttablet (extended-release)750 mgoralSunovion Pharmaceuticals Canada Inc2009-05-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niodan 500 Mg Time Release Tabletstablet (extended-release)500 mgoralOdan Laboratories Ltd1991-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sustained Release Niacin 500mgtablet (extended-release)500 mgoralKsl Pharmaceuticals1994-12-311997-08-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Time Released Niacin 500 mgtablet (extended-release)500 mgoralHealth Wise Nutrition Inc.1997-08-152000-07-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Niacintablet, extended release750 mg/1oralLUPIN LIMITED2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release500 mg/1oralTeva Pharmaceuticals USA Inc2013-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release500 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-07-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release1000 mg/1oralLupin Pharmaceuticals, Inc.2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release750 mg/1oralSun Pharma Global FZE2014-06-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release750 mg/1oralLupin Pharmaceuticals, Inc.2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release1000 mg/1oralSun Pharma Global FZE2014-06-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release500 mg/1oralLupin Pharmaceuticals, Inc.2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release500 mg/1oralSun Pharma Global FZE2014-06-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release750 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release1000 mg/1oralAmerican Health Packaging2014-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release1000 mg/1oralTeva Pharmaceuticals USA Inc2013-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release500 mg/1oralAmerican Health Packaging2014-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release500 mg/1oralLUPIN LIMITED2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release1000 mg/1oralLUPIN LIMITED2014-03-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release750 mg/1oralTeva Pharmaceuticals USA Inc2013-09-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, extended release1000 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-07-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacintablet, film coated, extended release750 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-12-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacortablet500 mg/1oralUpsher Smith Laboratories Inc.2000-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acti-niacin Caplet 500mgtablet500 mgoralActi Form Ltd.1991-12-312005-03-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
B3tablet500 mgoralNatural Factors Nutritional Products Ltd.1997-12-302008-07-17Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Formula # 7 Tab 50mgtablet50 mgoralGolden Pride/Rawleigh1995-12-312004-10-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jeuncell Hair Restorer and Hair Growth Solutionshampoo2 mg/100mLtopicalJeun Cell Ltd2012-11-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Niacin 100 mgcapsule100 mgoralFlora Manufacturing And Distributing Ltd.2002-03-152004-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 100 Mg Tabletstablet100 mgoralGeneral Nutrition Canada Inc.1997-04-182005-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 100mgtablet100 mgoralGreat Earth Companies, Inc.1998-08-252002-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 100mgtablet100 mgoralValeant Canada Lp Valeant Canada S.E.C.1973-12-312014-05-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 100mg Tabtablet100 mgoralGahler Enterprises Ltd.1984-12-312009-09-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 100mg Tablets USPtablet100 mgoralPharmetics (2011) Inc1999-08-082006-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 250mgtablet250 mgoralGreat Earth Companies, Inc.1998-08-252002-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 500mgtablet500 mgoralGreat Earth Companies, Inc.1998-08-252002-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 500mgtablet500 mgoralValeant Canada Lp Valeant Canada S.E.C.1976-12-312014-04-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin 50mgtablet50 mgoralGreat Earth Companies, Inc.1998-08-252002-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Cap 250mgcapsule250 mgoralQuest Vitamins A Div Of Purity Life Health Products1984-12-312001-07-06Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Caps 100mgcapsule100 mgoralTwin Laboratories Inc.1995-12-311999-11-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Src 400mgcapsule (sustained-release)400 mgoralAnabolic Laboratories Inc.1981-12-311996-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 100mgtablet100 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1957-12-312002-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 100mgtablet100 mgoralNu Life Nutrition Ltd.1987-12-312005-03-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 100mg USPtablet100 mgoralPharmavite Llc1987-12-312000-08-24Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 100mg Yeast Freetablet100 mgoralVita Health Products Inc1972-12-312004-07-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 250mgtablet250 mgoralNutristar Health Products (1987) Inc.1986-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 475mgtablet (extended-release)475 mgoralPure Life International Prods Inc.1992-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 500mgtablet500 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1957-12-312002-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 500mgtablet500 mgoralKlaire Labs Inc.1984-12-311999-01-18Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 500mgtablet500 mgoralQuest Vitamins A Div Of Purity Life Health Products1978-12-311998-07-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tab 50mgtablet50 mgoralPro Doc Limitee1983-12-312003-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin Tablets 500mg USPtablet500 mgoralKsl Pharmaceuticals1990-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Niacin-100 Tab 100mgtablet100 mgoralPro Doc Limitee1983-12-312003-07-31Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tri B3 Src 300mgcapsule (sustained-release)300 mgoralAnabolic Laboratories Inc.1976-12-312004-03-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vitamin B3 Tab 10mg USP Chewabletablet10 mgoralLab Gernetic Int Ltee1985-12-311997-02-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AdvicorAbb Vie Inc.
Antivert TabPfizer Canada Inc
B 6 PlusAnabolic Laboratories Inc.
B-plexLand Art Inc.
B6 Plus TabVita Health Products Inc
Balanced B-50 ComplexLeiner Health Products Inc.
C-B ComplexAvacare, Division Of Jeunique International Inc.
Cc IIAdded Dimensions
Cda-21 Vitamins With Non-medicinal Probiotic ComplexRx Vitamins Inc.
Complex 5 - PwrAst Research
Concept DHAUs Pharmaceutical Corporation
Concept ObUs Pharmaceutical Corporation
Cool BSisu Inc.
Formula Sf-710Thorne Research Inc.
Hi Potency Balanced B-100 Complex - TabLeiner Health Products Inc.
Hill.viteHillestad Pharmaceuticals Usa
IfbVisiontel
Integra FUs Pharmaceutical Corporation
Integra PlusUs Pharmaceutical Corporation
LipovitanP.S.W.C. Co., Inc.
Metacinamide TabMetagenics, Inc.
MhbVisiontel
Multi #2W 7 Clay Inc.
Multi-vitaminLLC Federal Solutions
Multi-vitamin Fluoride and Iron DropsBoca Pharmacal, LLC
Multi-vitamin Fluoride DropsH.J. Harkins Company, Inc.
Multi-vitamin With FluorideGolden State Medical Supply, Inc.
Multi-vitamins for Infusion LiqDavid Bull Laboratories (Pty) Ltd.
Mvc-fluorideSancilio & Company Inc.
Nata KompleteWh Nutritionals, Llc
NephrocapsCardinal Health
Ni-C-E-LE PlusNutrimetics International (Canada) Inc.
Niacin-niacinamide TabSeroyal International Inc.
O-cal Prenatal VitaminPharmics, Inc.
Prenatal Mega AntioxidantUsana Health Services, Inc.
Prenatal Vitamins Plusbryant ranch prepack
Reaphirm Plant Source DHAEverett Laboratories, Inc.
Red BullP.S.W.C. Co., Inc.
Remedium - Liq OrlF.E.S. Trading Canada Ltd.
Reno CapsNnodum Pharmaceuticals
RogenicEnzymatic Therapy (Canada) Inc.
Shen Min Vitamin SupplementBiotech Corporation
SimcorAbb Vie Inc.
Stress Formula Multivitamin Tablets USPLeiner Health Products Inc.
Strovite Forte CapletEverett Laboratories, Inc.
SveetsSensible Delights Specialty Foods
Vitafol CapletEverett Laboratories, Inc.
Vitafol Ob CapletEverett Laboratories, Inc.
Vitafol OneEverett Laboratories, Inc.
Vitafol PlusEverett Laboratories, Inc.
Vitamin B Complex TabNutristar Health Products (1987) Inc.
Vitamin B Compound TabNutrilite, A Division Of Access Business Group, Llc
SaltsNot Available
Categories
UNII2679MF687A
CAS number59-67-6
WeightAverage: 123.1094
Monoisotopic: 123.032028409
Chemical FormulaC6H5NO2
InChI KeyInChIKey=PVNIIMVLHYAWGP-UHFFFAOYSA-N
InChI
InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
IUPAC Name
pyridine-3-carboxylic acid
SMILES
OC(=O)C1=CN=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinecarboxylic acids and derivatives
Direct ParentPyridinecarboxylic acids
Alternative Parents
Substituents
  • Pyridine carboxylic acid
  • Heteroaromatic compound
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
PharmacodynamicsNiacin and niacinamide are indicated for prevention and treatment of vitamin B3 deficiency states. Vitamin B3 (Niacin) also acts to reduce LDL cholesterol, triglycerides, and HDL cholesterol. The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality. The increase in total HDL is associated with a shift in the distribution of HDL subfractions (as defined by ultra-centrifugation) with an increase in the HDL2:HDL3 ratio and an increase in apolipoprotein A-I content. Vitamin B3 (Niacin) treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions, and of lipoprotein-a, a variant form of LDL independently associated with coronary risk.
Mechanism of actionNiacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.
AbsorptionBoth nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life20-45 minutes.
ClearanceNot Available
ToxicityNicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD50 7000 mg/kg (Rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9672
Blood Brain Barrier+0.9648
Caco-2 permeable+0.8701
P-glycoprotein substrateNon-substrate0.8683
P-glycoprotein inhibitor INon-inhibitor0.9935
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.8938
CYP450 2C9 substrateNon-substrate0.8246
CYP450 2D6 substrateNon-substrate0.9231
CYP450 3A4 substrateNon-substrate0.8381
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.94
CYP450 3A4 inhibitorNon-inhibitor0.912
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9875
Ames testNon AMES toxic0.9939
CarcinogenicityNon-carcinogens0.8566
BiodegradationReady biodegradable0.9437
Rat acute toxicity1.2760 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9557
hERG inhibition (predictor II)Non-inhibitor0.9829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Barr laboratories inc
  • Abbott laboratories
  • Everylife
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mk laboratories inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Tablicaps inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Wockhardt ltd
  • Upsher smith laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tablet (immediate release); tablet (extended-release)oral
Tablet, extended releaseoral
Powderoral
Tabletoral50 mg
Shampootopical2 mg/100mL
Liquidoral
Solutionoral
Liquidintravenous
Tablet, chewableoral
Tablet, extended releaseoral1000 mg/1
Tablet, extended releaseoral500 mg/1
Tablet, extended releaseoral750 mg/1
Tabletoral250 mg
Capsuleoral250 mg
Capsuleoral100 mg
Tablet (extended-release)500 mg
Solutionintramuscular; intravenous100 mg
Powderoral800 mg
Capsule (sustained-release)oral400 mg
Tabletoral100 mg
Tablet (extended-release)oral475 mg
Tabletoral500 mg
Tabletoral500 mg/1
Tablet (extended-release)oral1000 mg
Tablet, film coated, extended releaseoral1000 mg/1
Tablet, film coated, extended releaseoral500 mg/1
Tablet, film coated, extended releaseoral750 mg/1
Tablet (extended-release)oral750 mg
Tablet (extended-release)oral500 mg
Tablet, film coated, extended releaseoral
Tablet, coatedoral
Lozengeoral
Capsule (sustained-release)oral300 mg
Capsuleoral
Tabletoral
Capsule, gelatin coatedoral
Capsule, liquid filledoral
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Niaspan 1000 mg Controlled Release Tabs4.67USD tab
Simcor 1000-20 mg 24 Hour tablet4.67USD tablet
Niaspan er 1000 mg tablet4.49USD tablet
Simcor 1000-20 mg tablet4.49USD tablet
Niaspan 1000 mg tablet er4.04USD tablet
Niaspan 750 mg Controlled Release Tabs3.76USD tab
Niaspan er 750 mg tablet3.62USD tablet
Simcor 750-20 mg tablet3.62USD tablet
Niaspan 750 mg tablet er3.25USD tablet
Niaspan 500 mg Controlled Release Tabs2.65USD tab
Simcor 500-20 mg 24 Hour tablet2.64USD tablet
Niaspan er 500 mg tablet2.54USD tablet
Simcor 500-20 mg tablet2.54USD tablet
Niaspan 500 mg tablet er2.28USD tablet
Nicomide-t 4% cream1.1USD g
Niacinamide ascorbate powder0.57USD g
Niacin flush free 750 mg capsule0.35USD capsule
Niacinamide powder0.24USD g
Slo-niacin 750 mg tablet0.19USD tablet
Niacin 500 mg capsule0.16USD capsule
Slo-niacin 500 mg tablet0.14USD tablet
Niacin 500 mg tablet0.1USD tablet
Slo-niacin 250 mg tablet0.09USD tablet
Niacin 1000 mg tablet sa0.08USD tablet
No flush niacin capsule0.08USD capsule
Niacin 250 mg tablet sa0.06USD tablet
Niacin flush free 500 mg capsule0.06USD capsule
Niacin 250 mg tablet0.03USD tablet
Niacinamide 500 mg tablet0.03USD tablet
Niacin 100 mg caplet0.02USD caplet
Niacin 100 mg tablet0.02USD tablet
Niacin 50 mg tablet0.02USD tablet
Niacinamide 100 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada22831592007-06-192018-03-06
Canada22985492006-01-102018-07-31
United States61299301993-09-202013-09-20
United States64690351998-03-152018-03-15
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point236.6 °CPhysProp
water solubility1.8E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.36SANGSTER (1993)
logS-0.84ADME Research, USCD
pKa4.75 (at 25 °C)DEAN,JA (1985)
Predicted Properties
PropertyValueSource
Water Solubility83.1 mg/mLALOGPS
logP0.29ALOGPS
logP-0.17ChemAxon
logS-0.17ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)4.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.19 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity31.16 m3·mol-1ChemAxon
Polarizability11.3 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.87 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)splash10-1z00000000-5daf0093df6c21c7279fView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)splash10-0z00000000-f38b6609b45de8c74565View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-1z00000000-4f55c81a6cd42f1b961dView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)splash10-lz00000000-00bf3662b5b9db533c0aView in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-az00000000-7820ea736b03b71d2cb8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-5z00000000-27508608b33f1fb9f221View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-z500000000-a2037c9695659dceabd1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-z400000000-4a2649a83ad2a40e5194View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-tz00000000-1bc47d1b1850f54fb7c2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-5z00000000-a352c5ce16d4b682b052View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-z300000000-ab23ecb032e387b40bd9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-z000000000-02e37a1cfd3947037579View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-z000000000-75d7e6658d2d6eca736eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-z000000000-21a2d68d4f364c596f1dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-2z00000000-a74db528f61c435876c8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-oz00000000-773c08ab92ace4d48a9cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-z600000000-07b12fbe942e6c7fb12dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-z000000000-66e0a5ba2ca8dbba1ed5View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-z000000000-fbf8ba47b56d7cc7be81View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-0z00000000-eaf82f6ab0befde118e9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positivesplash10-0z00000000-eaf82f6ab0befde118e9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-zd00000000-b1a48f694fba565108a1View in MoNA
MSMass Spectrum (Electron Ionization)splash10-vz00000000-7d3f033a49f5fad75f33View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,1H] 2D NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Joseph E. Toomey, Jr., “Electrochemical synthesis of niacin and other N-heterocyclic compounds.” U.S. Patent US5002641, issued 1914.

US5002641
General References
  1. Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. Pubmed
External Links
ATC CodesC04AC01C10AD02
AHFS Codes
  • 24:06.92
  • 88:08.00
PDB Entries
FDA labelDownload (330 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Niacin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Niacin.
AtorvastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Atorvastatin.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Niacin.
CholestyramineCholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColesevelamColesevelam can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Niacin.
FluvastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Fluvastatin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Niacin.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Niacin.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Niacin.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Niacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Niacin.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Niacin.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Niacin.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Niacin.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Niacin.
Insulin RegularThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Niacin.
Insulin, isophaneThe therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Niacin.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Niacin.
LovastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Lovastatin.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.
PitavastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Pitavastatin.
PravastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Pravastatin.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Niacin.
RosuvastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Rosuvastatin.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Niacin.
SimvastatinThe risk or severity of adverse effects can be increased when Niacin is combined with Simvastatin.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Niacin.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Niacin.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

1. Hydroxycarboxylic acid receptor 3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Hydroxycarboxylic acid receptor 3 P49019 Details

References:

  1. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3. Pubmed
  2. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG: (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52. Epub 2005 Jun 1. Pubmed
  3. Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, Wang H, Su EW, Mosior MK, Eacho PI, Cao G: Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32. Pubmed
  4. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S: Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol. 2005 Nov;68(5):1271-80. Epub 2005 Aug 11. Pubmed
  5. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S: GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005 Dec;115(12):3634-40. Pubmed
  6. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9. Pubmed

2. Hydroxycarboxylic acid receptor 2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Hydroxycarboxylic acid receptor 2 Q8TDS4 Details

References:

  1. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9. Pubmed
  2. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K: Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003 Mar 28;303(1):364-9. Pubmed
  3. Zellner C, Pullinger CR, Aouizerat BE, Frost PH, Kwok PY, Malloy MJ, Kane JP: Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat. 2005 Jan;25(1):18-21. Pubmed
  4. Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, Wang H, Su EW, Mosior MK, Eacho PI, Cao G: Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun. 2005 Aug 26;334(2):729-32. Pubmed
  5. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S: Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol. 2005 Nov;68(5):1271-80. Epub 2005 Aug 11. Pubmed

3. Nicotinate-nucleotide pyrophosphorylase [carboxylating]

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: binder

Components

Name UniProt ID Details
Nicotinate-nucleotide pyrophosphorylase [carboxylating] Q15274 Details

References:

  1. Fukuwatari T, Morikawa Y, Hayakawa F, Sugimoto E, Shibata K: Influence of adenine-induced renal failure on tryptophan-niacin metabolism in rats. Biosci Biotechnol Biochem. 2001 Oct;65(10):2154-61. Pubmed
  2. Shin DH, Oganesyan N, Jancarik J, Yokota H, Kim R, Kim SH: Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum. J Biol Chem. 2005 May 6;280(18):18326-35. Epub 2005 Mar 6. Pubmed
  3. Zheng XQ, Hayashibe E, Ashihara H: Changes in trigonelline (N-methylnicotinic acid) content and nicotinic acid metabolism during germination of mungbean (Phaseolus aureus) seeds. J Exp Bot. 2005 Jun;56(416):1615-23. Epub 2005 Apr 18. Pubmed

4. Nicotinamide N-methyltransferase

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: binder

Components

Name UniProt ID Details
Nicotinamide N-methyltransferase P40261 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Riederer M, Erwa W, Zimmermann R, Frank S, Zechner R: Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis. 2009 Jun;204(2):412-7. Epub 2008 Sep 27. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Solute carrier family 22 member 5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 5 O76082 Details

References:

  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. Pubmed

2. Solute carrier organic anion transporter family member 2B1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 2B1 O94956 Details

References:

  1. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. Pubmed

3. Monocarboxylate transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Monocarboxylate transporter 1 P53985 Details

References:

  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. Pubmed

4. Sodium-coupled monocarboxylate transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sodium-coupled monocarboxylate transporter 1 Q8N695 Details

References:

  1. Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. Pubmed

5. Monocarboxylate transporter 4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Monocarboxylate transporter 4 O15427 Details

References:

  1. Shimada A, Nakagawa Y, Morishige H, Yamamoto A, Fujita T: Functional characteristics of H+ -dependent nicotinate transport in primary cultures of astrocytes from rat cerebral cortex. Neurosci Lett. 2006 Jan 16;392(3):207-12. Epub 2005 Oct 5. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11